AI / data analytics / healthtech / informatics

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biomarkers #Business #Computational chemistry #Drug development #Gene editing #Genomics #Immunology #RNA #Screening #System biology #Systems biology

Still time to register for SLAS Transformed 2020

22 June 2020 SLAS Transformed is an interactive event focused on omics, synthetic biology and genome editing along with applicable implications for the current pandemic. The two-day event runs from 23-24 June 2020, offering 30-minute scientific research presentations, live exhibitor presentations and one-on-one networking sessions. It will span multiple… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Business #Cell therapy #Cellular assays #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Oncology #Regulatory #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

CatalYm to present data on immunotherapy of cancer at AACR Annual Meeting

19 June 2020 CatalYm will be presenting two abstracts identifying a novel immunoregulatory role for Growth-and-Differentiation Factor 15 (GDF-15) and its effective neutralisation by CTL-002 antibody in cancer at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on 22-24 June. Tumor-derived GDF-15 suppresses T-lymphocyte recruitment… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Business #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Pharmacology #Screening #Stem cells #Therapeutics #Translational #Translational chemistry

Dexamethasone identified as potential for treatment of COVID-19 ten weeks ago

AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate drug discovery, has announced that its platform identified dexamethasoneas having high potential for the treatment of COVID-19 in April 2020. AI VIVO, a company combining systems pharmacology and artificial intelligence (AI) to accelerate… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Analysis #Clinical specialities #Clinical trials #High Content Screening

AstraZeneca to present new data in treating type-2 diabetes

11 June, 2020 The British-Swedish multinational is to present new data from the landmark Phase III DAPA-HF and DECLARE-TIMI 58 trials at the upcoming 80th American Diabetes Association (ADA) Virtual Scientific Sessions, taking place June 12-26. According to AstraZeneca, the data to be presented is among 23 accepted… Read More

#News

#AI / data analytics / healthtech / informatics #Automation / robotics #Business #Clinical trials

Global life sciences alliance launches digital healthcare initiative

10 June, 2020 The Pistoia Alliance, a global, not-for-profit alliance that works to lower barriers to innovation in life sciences R&D, has launched a new series of programmes to help organisations collaborate on advancing the role of digital technology within life sciences R&D and healthcare. As part of… Read More

#News

#Academic #AI / data analytics / healthtech / informatics #Biomarkers #Business #Chemistry #Clinical specialities #Drug development #Drug discovery #Medicinal chemistry #RNA #System biology #Systems biology #Therapeutics

What will post-Covid-19 biotechnology look like?

Collaborative Drug Discovery (CDD), owner of the CDD Vault, a comprehensive drug discovery informatics platform for research laboratories, has asked researchers what they think biotechnology world will look like after Covid-19. A few responses are listed below. “Covid-19 may be the tipping point that shifts us from the… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The CRISPR revolution arrives in immuno-oncology

The CRISPR revolution arrives in immuno-oncology By Helen Stewart-Miller and Thomas Hope Volume 21 Issue 2 - Spring 2020 CRISPR-cas9 technology is having an exciting impact on drug discovery as a whole, but more specifically CRISPR presents enormous opportunities in targeted screening for immuno-oncology research. Clustered regularly-interspaced short palindromic repeats… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Mass spectrometry / NMR #Medicinal chemistry #Molecular medicine #Oncology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #System biology #Systems biology #Therapeutics

Meeting analytical challenges in a brave new world of next generation biotherapeutics

Meeting analytical challenges in a brave new world of next generation biotherapeutics By Mani Krishnan and Susan Darling Volume 21 Issue 2 - Spring 2020 The need for innovative advanced analytical tools to accelerate the development of immunotherapies and other complex biologics that may one day cure genetic diseases and… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Cancer research #Imaging #Lung cancer #Oncology

CIAN Lung: Exploring the potential of real-world data in lung cancer research

This article is sponsored by BC Platforms. Lung cancer ranks among the most prevalent and fatal cancers worldwide, prompting the need for improved treatment outcomes. Effective management relies on understanding tumour characteristics, including histology, clinical staging, and biomarkers. Despite progress in targeted therapies, ongoing research is… Read More

#News

#AI / data analytics / healthtech / informatics #Biomarkers #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Immunology #Oncology #PCR #Precision medicine #Regulatory #RNA #Therapeutics #Translational #Translational chemistry

Antimicrobial resistance threatens to undermine our healthcare system

Antimicrobial resistance threatens to undermine our healthcare system By Dr Peter Jackson Volume 21 Issue 2 - Spring 2020 The immediate global challenge to human health and our economic stability due to coronavirus acts as a stark reminder that infectious disease preparedness cannot be ignored. While antimicrobial resistance (AMR) does… Read More

#Exclusive Content

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biochemistry #Business #Chemical engineering #Chemistry #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Lead discovery #Medicinal chemistry #Organic chemistry #RNA #Screening #System biology #Systems biology #Toxicology #Translational #Translational chemistry

How sharing compound solubility data can advance drug discovery

By Andrii Lozoniuk Volume 21 Issue 2 - Spring 2020 Gathering compound solubility data is a key step during drug discovery that helps ensure cost-effective screening, yet it is a long process and is often underestimated in terms of difficulty. Global sharing of such data can help pharmaceutical companies minimise… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Biochemistry #Business #Cellular & Molecular biology #Chemistry #Drug development #Drug discovery #Drug targets #Gene editing #Genetics / genomes #Genomics #High throughput screening #Molecular medicine #Oncology #Orphan drugs #PCR #Precision medicine #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Target discovery and drug development what comes after CRISPR?

Target discovery and drug development what comes after CRISPR? By Benedict CS Cross Volume 21 Issue 2 - Spring 2020 For an area of research as important and impactful as drug discovery, it is surprising how often efforts in this field are directed by short-term trends. We have seen an… Read More

#Exclusive Content

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #In Silico Biology #Lead discovery #Molecular medicine #Oncology #Precision medicine #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Toxicology

Reprogramming the stem cell for a new generation of cures

Reprogramming the stem cell for a new generation of cures By Dr Alex Davenport, Dr Tonya Frolov and Dr Mark Kotter Volume 21 Issue 2 - Spring 2020 The development of new and effective treatments with the potential to cure, or at the very least ease patient suffering, has been… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Biomarkers #High Content Screening #Immunology #Lead discovery #RNA #Target validation

Mologic and Institut Pasteur de Dakar accelerate rapid diagnostic test for Ebola

Mologic has announced that it has launched an accelerated programme with the Institut Pasteur de Dakar, Senegal to develop a low-cost, high-performance rapid diagnostic test for Ebola Virus Disease (Ebola). The project is supported by the Wellcome Trust and the UK Government’s Department for International Development… Read More

#Covid-19 #News

#Academic #AI / data analytics / healthtech / informatics #Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Preclinical #RNA #System biology #Systems biology #Therapeutics

Drug development 2.0 – The partnership model in practice

Drug development 2.0 - The partnership model in practice By Dr Brian Sheehan and Marco Cerato Over the last decade there has been a fundamental shift in the way in which drugs are developed and brought to market. Some years ago, the industry started to see profits falling as research… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Medicinal chemistry #Oncology #PCR #Preclinical #RNA #Therapeutics

Cryo-EM accelerates drug discovery by delivering previously intractable structural insights

Cryo-EM accelerates drug discovery by delivering previously intractable structural insights By Hans Raaijmakers, et al. Cryo-electron microscopy (cryo-EM), a powerful biophysical technique that can analyse molecular assemblies, is changing the paradigm in structure-based drug design. As targets become more challenging, solving structures of drug target molecules or biologics becomes increasingly… Read More

#Archive